LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study
The Prostate · 2023
DOI: 10.1002/pros.24548 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Isabel E Jimenez-Garcia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Complejo Hospitalario Universitario de Albacete (CHUA), Albacete, Spain. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Purpose
To compare the clinical outcomes of single‐fraction high‐dose‐rate (HDR) brachytherapy and single‐fraction low‐dose‐rate (LDR) brachytherapy as the sole treatment for primary prostate cancer. Material and Methods A quasi‐randomized study that allocated, from March 2008 to February 2012 , 129 low and intermediate risk prostate cancer patients to one single‐fraction HDR of 19 Gy (61 patients) or to a 145 Gy 125 I LDR permanent implant (68 patients. Biochemical relapse‐free survival (bRFS) and overall survival (OS) were compared using the Kaplan–Meier method and Cox regression analysis.
Results
After a median follow‐up of 72 months in the HDR group, 26 patients relapsed, and after a median follow‐up of 84 months in the LDR group, 7 patients relapsed ( p < 0.0001). The 5‐year bRFS was significantly better for the LDR group than for the HDR group (93.7% and 61.1%, respectively) ( p < 0.0001). The 5‐year OS also was significantly better in the LDR group (95.5% vs. 89.9%) ( p = 0.0436).
Conclusions
Permanent LDR prostate implant brachytherapy offers better clinical outcomes than single‐fraction HDR for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Complejo Hospitalario Universitario de Albacete (CHUA), Albacete, Spain.
- Department of Radiation Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Radiation Physics, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Department of Radiation Physics, Complejo Hospitalario Universitario de Albacete (CHUA), Albacete, Spain.
- Laboratorio de Oncología Molecular, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Albacete,…
- Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Unidad Asociada de Biomedicina UCLM, Unidad asociada al CSIC, Madrid, Spain.
ORCID-Profile: Isabel E Jimenez-Garcia, Sebastia Sabater, Susana Castro-Larefors, Ricardo Sánchez-Prieto, Herminio A Gonzalez-Suarez
Zitieren
APA
Jimenez-Garcia, I. E., Sabater, S., Martinez-Gutierrez, R., Sanchez-Galiano, P., Berenguer-Serrano, R., Castro-Larefors, S., Rey-Lopez, I., Ruiz-Herrero, B., Sánchez-Prieto, R., Rovirosa, A., Arenas, M., & Gonzalez-Suarez, H. A. (2023). LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study. The Prostate. https://doi.org/10.1002/pros.24548
Vancouver
Jimenez-Garcia IE, Sabater S, Martinez-Gutierrez R, Sanchez-Galiano P, Berenguer-Serrano R, Castro-Larefors S, et al. LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study. The Prostate. 2023. doi:10.1002/pros.24548
BibTeX
@article{JimenezGarcia2023,
author = {Jimenez-Garcia, Isabel E and Sabater, Sebastia and Martinez-Gutierrez, Rocio and Sanchez-Galiano, Pedro and Berenguer-Serrano, Roberto and Castro-Larefors, Susana and Rey-Lopez, Irene and Ruiz-Herrero, Beatriz and Sánchez-Prieto, Ricardo and Rovirosa, Angeles and Arenas, Meritxell and Gonzalez-Suarez, Herminio A},
title = {LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24548}
}
EUVIMED